688338.SHG Beijing Succeeder Technology Inc
- Market cap
- CNY 2.78B
- P/E
- 32.7x
- P/B
- 1.56x
- ROE
- 4.6%
- Dividend yield
- 1.24%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688338.SHG undervalued?
Graham number688338.SHG trades 50.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Beijing Succeeder Technology Inc fundamental analysis
No fundamental analysis for Beijing Succeeder Technology Inc yet.
Beijing Succeeder Technology Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Beijing Succeeder Technology Inc
Beijing Succeeder Technology Inc. engages in the research, development, production, and sales of testing instruments, reagents, and consumables in the field of in vitro diagnostics for thrombosis and hemostasis in China and internationally. The company offers coagulation testers, hemorheology testers, erythrocyte sedimentation rate and hematocrit testers, platelet aggregation testers, blood rheology analyzer, diagnostic reagents, and quality control products, as well as auto…
Full company profileBeijing Succeeder Technology Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Beijing Succeeder Technology Inc annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 125M | 157M | 200M | 230M | 222M | 240M | 229M | 275M | 306M | 264M | 259M |
| Gross Profit | 71.0M | 90.5M | 116M | 136M | 131M | 144M | 143M | 171M | 188M | 264M | 164M |
| Operating Income | 33.7M | 36.7M | 65.5M | 81.7M | 84.8M | 108M | 118M | 135M | 130M | 103M | 79.4M |
| EBITDA | 35.3M | 39.6M | 65.6M | 84.9M | 81.7M | 121M | 127M | 141M | 142M | 115M | 91.0M |
| Net Income | 31.0M | 29.3M | 56.7M | 71.0M | 69.2M | 97.4M | 104M | 117M | 113M | 87.1M | 79.2M |
| EPS | 0.44 | 0.40 | 0.77 | 0.67 | 0.65 | 0.92 | 0.98 | 1.10 | 1.07 | 0.84 | 0.75 |
| Balance Sheet | |||||||||||
| Total Assets | 155M | 186M | 243M | 427M | 1.40B | 1.48B | 1.61B | 1.71B | 1.75B | 1.77B | 1.79B |
| Total Liabilities | 50.9M | 43.0M | 47.3M | 52.0M | 45.3M | 62.9M | 107M | 106M | 102M | 75.9M | 66.5M |
| Shareholders' Equity | 104M | 143M | 196M | 375M | 1.36B | 1.42B | 1.50B | 1.60B | 1.65B | 1.69B | 1.72B |
| Cash & Short-term Investments | 91.8M | 108M | 159M | 323M | 1.27B | 1.32B | 1.31B | 1.28B | 1.27B | 780M | 804M |
| Total Debt | - | - | - | - | 6.29M | 4.17M | 738K | 182K | 61.6K | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 35.3M | 32.7M | 58.2M | 60.9M | 72.3M | 107M | 101M | 110M | 123M | 79.4M | - |
| Capital Expenditure | 4.50M | 2.54M | 3.85M | 5.10M | 32.3M | 15.7M | 97.2M | 120M | 72.4M | 33.7M | 4.59M |
| Free Cash Flow | 30.8M | 30.1M | 54.3M | 55.8M | 40.0M | 91.7M | 3.31M | -10.6M | 50.6M | 45.7M | 63.7M |
| Ratios | |||||||||||
| ROE | 29.9% | 20.5% | 29.0% | 19.0% | 5.1% | 6.9% | 6.9% | 7.3% | 6.9% | 5.2% | 4.6% |
| ROA | 20.0% | 15.8% | 23.3% | 16.6% | 4.9% | 6.6% | 6.5% | 6.9% | 6.5% | 4.9% | 4.4% |
| Net Profit Margin | 24.7% | 18.7% | 28.3% | 30.9% | 31.1% | 40.6% | 45.5% | 42.4% | 36.9% | 33.1% | 30.6% |
| Debt to Equity | - | - | - | - | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Beijing Succeeder Technology Inc dividends
- Dividend yield
- 1.24%
- Forward dividend
- 0.26 CNY
- Payout ratio
- 39.4%
- Ex-dividend date
- Jun 4, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 34.3M | 0.33 | 39.4% |
| 2024 | CNY 27.6M | 0.26 | 24.4% |
| 2023 | CNY 21.2M | 0.20 | 18.2% |
| 2022 | CNY 20.4M | 0.19 | 19.6% |
| 2021 | CNY 32.7M | 0.31 | 33.5% |
| 2020 | CNY 12.0M | 0.11 | 17.3% |
| 2019 | CNY 960K | 0.01 | 1.4% |
| 2018 | CNY 4.04M | 0.05 | 7.1% |
| 2017 | CNY 19.3M | 0.26 | 65.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.3:1 on Jul 7, 2023.
Who owns Beijing Succeeder Technology Inc
- Insiders 55.58%
- Institutions 1.63%
- Public & others 42.79%
- Shares outstanding 106M
- Free float 46.1M
Beijing Succeeder Technology Inc company profile
- Company name
- Beijing Succeeder Technology Inc
- Ticker
- 688338.SHG
- ISIN
- CNE1000044C4
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 268
- Fiscal year end
- December
- Address
- No.19 Baili Street, Beijing, China, 102600
- Phone
- 86 10 8928 1810
- Website
- succeeder.com.cn
About Beijing Succeeder Technology Inc
Beijing Succeeder Technology Inc. engages in the research, development, production, and sales of testing instruments, reagents, and consumables in the field of in vitro diagnostics for thrombosis and hemostasis in China and internationally. The company offers coagulation testers, hemorheology testers, erythrocyte sedimentation rate and hematocrit testers, platelet aggregation testers, blood rheology analyzer, diagnostic reagents, and quality control products, as well as automated equipment with supporting testing instruments. Its products are used in the prevention, screening, diagnosis, and monitoring of thrombophilia and hemorrhagic diseases, such as stroke, coronary heart disease, and venous thromboembolism. Beijing Succeeder Technology Inc. was founded in 2003 and is based in Beijing, China.
Beijing Succeeder Technology Inc management
8- Mr. Hai WangGM & Director · born 1971
- Mr. Guo LiFinancial Director, Accounting Supervisor & Director · born 1977
- Ms. Zhonghui DingDeputy GM & Director · born 1973
- Ms. Tong WuDirector & Deputy General Manager · born 1984
- Mr. Guobin LiuDeputy General Manager & Supervisor · born 1986
- Mr. Zhe RenDeputy General Manager & Core Technical Personnel · born 1985
- Mr. Jiahong ZhangBoard Secretary · born 1973
- Mr. Yanbin PeiDeputy General Manager · born 1967